Research Topic

Nano- and Micro-carrier Based Cardiovascular Drug Delivery

About this Research Topic

Cardiovascular diseases (CVDs), such as atherosclerosis, stroke, heart failure, peripheral vascular diseases, are the world’s leading causes of death and represent a major burden globally. CVD patients could considerably benefit from innovative nanomedicine imaging tools and treatments. In particular, micro- and nano- carriers could facilitate the efficient and selective delivery of active pharmaceutical ingredients (API) in the required location for their targeted action (e.g., thrombus, atherosclerotic lesions) while reducing side-effects. Nanotechnology-based approaches for drug delivery have now entered clinical practice in the field of oncology and neurology, demonstrating the possibility of nano- and micro- carriers to successfully overcome targeted delivery issues and thereby transforming clinical practice. It is now time for cardiovascular disease area to also benefit from such macro- or nano-based therapeutic strategies.

The use of micro- and nano-carriers for delivering drug payload in specific and localized targeted locations is exciting in many ways. First, micro- and nano- carriers provide suitable containers to enhance drug solubilization and increased payload. They can also protect API against degradation in physiological medium and overcome biological barriers until reaching their site or time of action.
Due to the multiplicity of biological processes involved in CVDs, different targeting approaches have also been proposed in the literature to specifically increase the uptake of micro- and nano- vectors in atherosclerotic lesions or in thrombi, through various surface functionalization. These targeting strategies are to be further developed or combined, in order to further improve the selectivity of the delivery and control the kinetics of drug release.
Depending on the targeting strategy and drug payload, a large variety of micro- or nano-carriers can be employed (e.g., liposomes, lipoprotein-based nanoparticles, polymer or lipid nanoparticles). These carriers can be administered as such, loaded in polymer materials processed as stents, pills or other devices. Different delivery routes for these nano- and micro-carriers should be developed, explored and compared, to improve patient compliance to treatments, especially for long-term, chronic treatments.

In this Research Topic, manuscripts (original research, review, mini-reviews and opinions) describing all types of drug delivery systems either at the micro- or nanoscales are welcome, providing an overview of the state of the art, as well as highlighting recent discoveries and future prospects. Potential topics include, but are not limited to, polymeric nanocarriers (micelles, nanoparticles, nanocapsules, dendrimers), lipid-based nanocarriers (nanoparticles and liposomes), lipoproteins, drug nanoencapsulation and nanogels. Manuscripts are sought that describe innovative micro- or nano-carriers, their targeting strategy, and their formulation for different delivery routes. In particular, we highly encourage submissions with translational potential.


Keywords: Polymeric Nanoparticles, Nanogels, Dendrimers, Micelles, Lipid Nanoparticles, Lipoproteins, Nanotherapeutics, Anti-inflammatory, Anti-thrombolytics


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

Cardiovascular diseases (CVDs), such as atherosclerosis, stroke, heart failure, peripheral vascular diseases, are the world’s leading causes of death and represent a major burden globally. CVD patients could considerably benefit from innovative nanomedicine imaging tools and treatments. In particular, micro- and nano- carriers could facilitate the efficient and selective delivery of active pharmaceutical ingredients (API) in the required location for their targeted action (e.g., thrombus, atherosclerotic lesions) while reducing side-effects. Nanotechnology-based approaches for drug delivery have now entered clinical practice in the field of oncology and neurology, demonstrating the possibility of nano- and micro- carriers to successfully overcome targeted delivery issues and thereby transforming clinical practice. It is now time for cardiovascular disease area to also benefit from such macro- or nano-based therapeutic strategies.

The use of micro- and nano-carriers for delivering drug payload in specific and localized targeted locations is exciting in many ways. First, micro- and nano- carriers provide suitable containers to enhance drug solubilization and increased payload. They can also protect API against degradation in physiological medium and overcome biological barriers until reaching their site or time of action.
Due to the multiplicity of biological processes involved in CVDs, different targeting approaches have also been proposed in the literature to specifically increase the uptake of micro- and nano- vectors in atherosclerotic lesions or in thrombi, through various surface functionalization. These targeting strategies are to be further developed or combined, in order to further improve the selectivity of the delivery and control the kinetics of drug release.
Depending on the targeting strategy and drug payload, a large variety of micro- or nano-carriers can be employed (e.g., liposomes, lipoprotein-based nanoparticles, polymer or lipid nanoparticles). These carriers can be administered as such, loaded in polymer materials processed as stents, pills or other devices. Different delivery routes for these nano- and micro-carriers should be developed, explored and compared, to improve patient compliance to treatments, especially for long-term, chronic treatments.

In this Research Topic, manuscripts (original research, review, mini-reviews and opinions) describing all types of drug delivery systems either at the micro- or nanoscales are welcome, providing an overview of the state of the art, as well as highlighting recent discoveries and future prospects. Potential topics include, but are not limited to, polymeric nanocarriers (micelles, nanoparticles, nanocapsules, dendrimers), lipid-based nanocarriers (nanoparticles and liposomes), lipoproteins, drug nanoencapsulation and nanogels. Manuscripts are sought that describe innovative micro- or nano-carriers, their targeting strategy, and their formulation for different delivery routes. In particular, we highly encourage submissions with translational potential.


Keywords: Polymeric Nanoparticles, Nanogels, Dendrimers, Micelles, Lipid Nanoparticles, Lipoproteins, Nanotherapeutics, Anti-inflammatory, Anti-thrombolytics


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Topic Editors

Loading..

Submission Deadlines

19 November 2021 Abstract
28 February 2022 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..

Topic Editors

Loading..

Submission Deadlines

19 November 2021 Abstract
28 February 2022 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..
Loading..

total views article views article downloads topic views

}
 
Top countries
Top referring sites
Loading..